Your browser doesn't support javascript.
loading
Attacking Latent HIV with convertibleCAR-T Cells, a Highly Adaptable Killing Platform.
Herzig, Eytan; Kim, Kaman Chan; Packard, Thomas A; Vardi, Noam; Schwarzer, Roland; Gramatica, Andrea; Deeks, Steven G; Williams, Steven R; Landgraf, Kyle; Killeen, Nigel; Martin, David W; Weinberger, Leor S; Greene, Warner C.
Afiliação
  • Herzig E; Gladstone Center for HIV Cure Research, Gladstone Institute of Virology and Immunology, San Francisco, CA 94158, USA; Departments of Medicine and Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Kim KC; Xyphos Biosciences, Inc., South San Francisco, CA 94080, USA.
  • Packard TA; Gladstone Center for HIV Cure Research, Gladstone Institute of Virology and Immunology, San Francisco, CA 94158, USA; Departments of Medicine and Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Vardi N; Gladstone Center for Cell Circuitry, Gladstone Institutes, San Francisco, CA 94158, USA; Departments of Biochemistry and Biophysics and Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA 94158, USA.
  • Schwarzer R; Gladstone Center for HIV Cure Research, Gladstone Institute of Virology and Immunology, San Francisco, CA 94158, USA; Departments of Medicine and Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Gramatica A; Gladstone Center for HIV Cure Research, Gladstone Institute of Virology and Immunology, San Francisco, CA 94158, USA; Departments of Medicine and Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Deeks SG; Department of Medicine, University of California, San Francisco, San Francisco, CA 94110, USA.
  • Williams SR; Xyphos Biosciences, Inc., South San Francisco, CA 94080, USA.
  • Landgraf K; Xyphos Biosciences, Inc., South San Francisco, CA 94080, USA.
  • Killeen N; Xyphos Biosciences, Inc., South San Francisco, CA 94080, USA.
  • Martin DW; Xyphos Biosciences, Inc., South San Francisco, CA 94080, USA.
  • Weinberger LS; Gladstone Center for HIV Cure Research, Gladstone Institute of Virology and Immunology, San Francisco, CA 94158, USA; Gladstone Center for Cell Circuitry, Gladstone Institutes, San Francisco, CA 94158, USA; Departments of Biochemistry and Biophysics and Pharmaceutical Chemistry, University of Califo
  • Greene WC; Gladstone Center for HIV Cure Research, Gladstone Institute of Virology and Immunology, San Francisco, CA 94158, USA; Departments of Medicine and Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address: warner.greene@gladstone.ucsf.edu.
Cell ; 179(4): 880-894.e10, 2019 10 31.
Article em En | MEDLINE | ID: mdl-31668804
ABSTRACT
Current approaches to reducing the latent HIV reservoir entail first reactivating virus-containing cells to become visible to the immune system. A critical second step is killing these cells to reduce reservoir size. Endogenous cytotoxic T-lymphocytes (CTLs) may not be adequate because of cellular exhaustion and the evolution of CTL-resistant viruses. We have designed a universal CAR-T cell platform based on CTLs engineered to bind a variety of broadly neutralizing anti-HIV antibodies. We show that this platform, convertibleCAR-T cells, effectively kills HIV-infected, but not uninfected, CD4 T cells from blood, tonsil, or spleen and only when armed with anti-HIV antibodies. convertibleCAR-T cells also kill within 48 h more than half of the inducible reservoir found in blood of HIV-infected individuals on antiretroviral therapy. The modularity of convertibleCAR-T cell system, which allows multiplexing with several anti-HIV antibodies yielding greater breadth and control, makes it a promising tool for attacking the latent HIV reservoir.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Replicação Viral / Infecções por HIV / Anticorpos Anti-Idiotípicos / Imunoterapia Adotiva Limite: Animals / Humans Idioma: En Revista: Cell Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Replicação Viral / Infecções por HIV / Anticorpos Anti-Idiotípicos / Imunoterapia Adotiva Limite: Animals / Humans Idioma: En Revista: Cell Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos